Brief: PolarityTE Announces Submission Of Complete Response To FDA's Clinical Hold Correspondence For SkinTE Investigational New Drug Application

RegenETP,

20/12/2021 13:13

Dec 20 (Reuters) - PolarityTE Inc  PTE.O :
    * POLARITYTE ANNOUNCES SUBMISSION OF COMPLETE RESPONSE TO
FDA'S
CLINICAL HOLD CORRESPONDENCE FOR SKINTE® INVESTIGATIONAL NEW
DRUG APPLICATION
    * POLARITYTE INC - ANNOUNCES SUBMISSION OF COMPLETE RESPONSE
TO
FDA'S CLINICAL HOLD CORRESPONDENCE FOR SKINTE® INVESTIGATIONAL
NEW DRUG APPLICATION
    * POLARITYTE INC - COMPLETE RESPONSE TO HOLD ISSUES WAS
SUBMITTED
ON DECEMBER 17, 2021

Source text for Eikon:  ID:nPn9pf8Kda 
Further company coverage:  PTE.O